Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Blood Purif ; 32(1): 7-14, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21242686

RESUMEN

BACKGROUND: Oxidative stress is prevalent in dialysis patients and has been implicated in the pathogenesis of cardiovascular disease and anemia. Vitamin E is a fat-soluble antioxidant that plays a central role in reducing lipid peroxidation and inhibiting the generation of reactive oxygen species. The aim of this cross-over randomized study was to compare the effects of a vitamin E-coated polysulfone (Vit E PS) membrane and a non-vitamin E-coated polysulfone (PS) membrane on inflammatory markers and resistance to erythropoietin-stimulating agents (ESAs). METHODS: After a 1-month run-in period of standard bicarbonate dialysis with a synthetic membrane, 62 patients of both genders, and older than 18 years, dialysis vintage 48 ± 27 months, BMI 22 ± 3 (from 13 different dialysis units) were randomized (A-B or B-A) in a cross-over design to Vit E PS (treatment A) and to PS (treatment B) both for 6 months. C-reactive protein (CRP) and interleukin-6 (IL-6) concentrations were determined by a sandwich enzyme immunoassay at baseline and every 2 months; red blood cell count, ESA dose and ESA resistance index (ERI) were assessed monthly. RESULTS: Hemoglobin (Hb) levels significantly increased in the Vit E PS group from 11.1 ± 0.6 g/dl at baseline to 11.5 ± 0.7 at 6 months (p < 0.001) and remained unchanged in the PS group. Although ESA dosage remained stable during the observation periods in both groups, ERI was significantly reduced in the Vit E PS group from 10.3 ± 2.2 IU-dl/kg/g Hb week at baseline to 9.2 ± 1.7 at 6 months (p < 0.001). No significant variation of ERI was observed in the PS group. A significant reduction in plasma CRP and IL-6 levels was observed in the Vit E PS group: CRP from 6.7 ± 4.8 to 4.8 ± 2.2 mg/l (p < 0.001) and IL-6 from 12.1 ± 1.4 to 7.5 ± 0.4 pg/ml (p < 0.05). In the PS group, CRP varied from 6.2 ± 4.0 to 6.4 ± 3.7, and IL-6 from 10.6 ± 2.1 to 9.6 ± 3.5 (p = n.s.). CONCLUSIONS: Treatment with Vit E PS membranes seems to lead to a reduction in ESA dosage in HD patients; in addition, a low chronic inflammatory response may contribute to a sparing effect on exogenous ESA requirements.


Asunto(s)
Antioxidantes/farmacología , Biomarcadores/sangre , Eritropoyetina/farmacología , Hematínicos/farmacología , Fallo Renal Crónico/terapia , Diálisis Renal , Vitamina E/farmacología , Anciano , Anciano de 80 o más Años , Antioxidantes/uso terapéutico , Proteína C-Reactiva/análisis , Materiales Biocompatibles Revestidos/química , Estudios Cruzados , Ensayo de Inmunoadsorción Enzimática , Eritropoyetina/metabolismo , Femenino , Estudios de Seguimiento , Hematínicos/metabolismo , Hemoglobinas/análisis , Humanos , Interleucina-6/sangre , Italia , Fallo Renal Crónico/sangre , Fallo Renal Crónico/fisiopatología , Peroxidación de Lípido/efectos de los fármacos , Masculino , Persona de Mediana Edad , Estrés Oxidativo/efectos de los fármacos , Polímeros/química , Diálisis Renal/instrumentación , Diálisis Renal/métodos , Método Simple Ciego , Sulfonas/química , Vitamina E/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...